Drug intelligence / Profile preview

trazodone + pregabalin

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of trazodone, an antidepressant with sedative properties, and pregabalin, an anticonvulsant. This combination has been studied for the treatment of fibromyalgia, where trazodone improves sleep quality, depression, and anxiety, while pregabalin provides complementary analgesic effects. Clinical studies have shown that the combination potentiates improvement in fibromyalgia severity, depression, pain interference with daily activities, and bodily pain compared to trazodone alone.

Targets

CaV (Voltage-gated calcium channel protein complex)HRH1 (Histamine H1 Receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))SERT (Sodium-dependent serotonin transporter)ADRA1A (α1A)HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on trazodone + pregabalin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on trazodone + pregabalin.

Explore the full profile